

PRESS RELEASE

Caprotec bioanalytics increases series B Financing in Second Closing to Euro 5 Million

Berlin, Germany and Burlington, MA, May 9, 2011.

Caprotec bioanalytics, a privately held biopharmaceutical company offering the proprietary Capture Compound Mass Spectrometry (CCMS) platform technology for analyzing small molecule – protein interactions, today announced a second closing of Euro 1 million to its Series B funding, bringing the total for the round to Euro 5 million in equity. The capital increase was fully subscribed by LBBW Venture Capital GmbH, Stuttgart, joining existing investors Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and well-known private investors.

Prof. Dr. Hubert Köster, CEO caprotec bioanalytics GmbH commented:

“This additional funding from LBBW Venture will allow us to further leverage caprotec’s CCMS technology into additional markets as diagnostics and will put the company in a position to execute several large pharma partnerships at the same time.”

Dr. Harald Poth, Senior Investment Manager of LBBW Venture added.

“Caprotec’s CCMS technology has the potential to solve the most expensive problem in the pharmaceutical industry, the failure of drug candidates in clinical trials due to off target interactions. With caprotec’s functional proteomics platform it is possible to profile small molecule drug – protein interactions, including membrane proteins in the human proteome to reveal possible off-target proteins causing adverse side effects, early in the drug development process and to use that information to structurally optimize the drug candidates.”

About caprotec bioanalytics

Caprotec bioanalytics GmbH was established in 2006 and is headquartered in Berlin, Germany with a US subsidiary in Burlington, MA. It was founded by CEO Prof. Dr. Hubert Köster a serial entrepreneur , the founder of Sequenom (NASDAQ:SQNM), co-founder of US company Milligen/Biosearch and founder of Biosyntech GmbH, the first biotechnology company in Germany. The company focuses on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology in the areas of functional proteomics, drug development and development of biomarkers. The Company holds a vast portfolio of 41 international patents of which are 21 already granted.

For more information , contact:

caprotec bioanalytics GmbH
Prof. Dr. Hubert Köster
Volmerstr. 5
12489 Berlin-Adlershof
Tel. +49 30 6392 3990
Fax +49 30 6392 3989
Email: hubert.koester@caprotec.com

About LBBW Venture Capital GmbH

LBBW Venture is a subsidiary of Landesbank Baden-Württemberg and invests in Life Science, IT and industrial technology in Germany since more than ten years. Portfolio companies in the Life Science sector are Cellzome, Curacyte Pharmaceuticals, Phenex Pharmaceuticals, mtm laboratories and several fund in fund investments. Most recently the portfolio companies ProbioGen and Sloning were successfully sold.

Contact:

LBBW-Venture Capital GmbH

Dr. Harald Poth

Königstr. 10c

70173 Stuttgart

Tel. +49 711 305 89 20 61

Fax +49 711 305 89 20 99

Email: harald.poth@LBBW-venture.de